{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:04:51Z","timestamp":1778601891445,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan plc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s10384-020-00796-3","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:17:43Z","timestamp":1613693863000},"page":"295-305","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of fixed-combination brimonidine tartrate\/timolol maleate in primary open-angle glaucoma, including normal-tension glaucoma"],"prefix":"10.1007","volume":"65","author":[{"given":"Sang Woo","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joon Mo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Woong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joy","family":"Maglambayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Simonyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8137-8843","authenticated-orcid":false,"given":"Ki Ho","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"796_CR1","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jamaophthalmol.2019.3537","volume":"137","author":"J Enoch","year":"2019","unstructured":"Enoch J, McDonald L, Jones L, Jones PR, Crabb DP. Evaluating whether sight is the most valued sense. JAMA Ophthalmol. 2019;137:1317\u201320.","journal-title":"JAMA Ophthalmol"},{"key":"796_CR2","doi-asserted-by":"crossref","unstructured":"European Glaucoma Society. Terminology and guidelines for glaucoma (4th edition). https:\/\/bjo.bmj.com\/content\/bjophthalmol\/101\/4\/1.full.pdf. Accessed 22 Dec 2020.","DOI":"10.1136\/bjophthalmol-2016-EGSguideline.001"},{"key":"796_CR3","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0002-9394(98)00272-4","volume":"126","author":"Collaborative Normal-Tension Glaucoma Study Group","year":"1998","unstructured":"Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498\u2013505.","journal-title":"Am J Ophthalmol"},{"key":"796_CR4","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0002-9394(98)00223-2","volume":"126","author":"Collaborative Normal-Tension Glaucoma Study Group","year":"1998","unstructured":"Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126:487\u201397.","journal-title":"Am J Ophthalmol"},{"key":"796_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.preteyeres.2004.06.001","volume":"24","author":"CF Burgoyne","year":"2005","unstructured":"Burgoyne CF, Downs JC, Bellezza AJ, Suh JK, Hart RT. The optic nerve head as a biomechanical structure: a new paradigm for understanding the role of IOP-related stress and strain in the pathophysiology of glaucomatous optic nerve head damage. Prog Retin Eye Res. 2005;24:39\u201373.","journal-title":"Prog Retin Eye Res"},{"key":"796_CR6","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"MA Kass","year":"2002","unstructured":"Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701\u201313 (Discussion 829-30).","journal-title":"Arch Ophthalmol"},{"key":"796_CR7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/jop.2005.21.337","volume":"21","author":"ER Craven","year":"2005","unstructured":"Craven ER, Walters TR, Williams R, Chou C, Cheetham JK, Schiffman R. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2005;21:337\u201348.","journal-title":"J Ocul Pharmacol Ther"},{"key":"796_CR8","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1001\/archopht.124.9.1230","volume":"124","author":"MB Sherwood","year":"2006","unstructured":"Sherwood MB, Craven ER, Chou C, DuBiner HB, Batoosingh AL, Schiffman RM, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol. 2006;124:1230\u20138.","journal-title":"Arch Ophthalmol"},{"key":"796_CR9","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/IJG.0b013e3181bdb586","volume":"19","author":"RA Lewis","year":"2010","unstructured":"Lewis RA, Gross RL, Sall KN, Schiffman RM, Liu CC, Batoosingh AL. The safety and efficacy of bimatoprost\/timolol fixed combination: a 1-year double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma. 2010;19:424\u20136.","journal-title":"J Glaucoma"},{"key":"796_CR10","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/eye.2013.83","volume":"27","author":"T Realini","year":"2013","unstructured":"Realini T, Nguyen QH, Katz G, DuBiner H. Fixed-combination brinzolamide 1%\/brimonidine 0.2% vs monotherapy with brinzolamide or brimonidine in patients with open-angle glaucoma or ocular hypertension: results of a pooled analysis of two phase 3 studies. Eye (Lond). 2013;27:841\u20137.","journal-title":"Eye (Lond)"},{"key":"796_CR11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/IJG.0b013e3181507313","volume":"17","author":"JD Brandt","year":"2008","unstructured":"Brandt JD, Cantor LB, Katz LJ, Batoosingh AL, Chou C, Bossowska I. Bimatoprost\/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma. 2008;17:211\u20136.","journal-title":"J Glaucoma"},{"key":"796_CR12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/archophthalmol.2009.384","volume":"128","author":"EJ Higginbotham","year":"2010","unstructured":"Higginbotham EJ, Olander KW, Kim EE, Grunden JW, Kwok KK, Tressler CS. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study. Arch Ophthalmol. 2010;128:165\u201372.","journal-title":"Arch Ophthalmol"},{"key":"796_CR13","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2147\/OPTH.S46881","volume":"7","author":"JT Whitson","year":"2013","unstructured":"Whitson JT, Realini T, Nguyen QH, McMenemy MG, Goode SM. Six-month results from a Phase III randomized trial of fixed-combination brinzolamide 1% + brimonidine 0.2% versus brinzolamide or brimonidine monotherapy in glaucoma or ocular hypertension. Clin Ophthalmol. 2013;7:1053\u201360.","journal-title":"Clin Ophthalmol."},{"key":"796_CR14","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1016\/j.ophtha.2014.06.022","volume":"121","author":"T Aung","year":"2014","unstructured":"Aung T, Laganovska G, Hernandez Paredes TJ, Branch JD, Tsorbatzoglou A, Goldberg I. Twice-daily brinzolamide\/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension. Ophthalmology. 2014;121:2348\u201355.","journal-title":"Ophthalmology"},{"key":"796_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ajo.2016.08.022","volume":"171","author":"T Yamamoto","year":"2016","unstructured":"Yamamoto T, Ikegami T, Ishikawa Y, Kikuchi S. Randomized, controlled, phase 3 trials of carteolol\/latanoprost fixed combination in primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2016;171:35\u201346.","journal-title":"Am J Ophthalmol"},{"key":"796_CR16","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1177\/112067210501500508","volume":"15","author":"Go\u00f1i FJ, Brimonidine\/Timolol Fixed Combination Study Group","year":"2005","unstructured":"Go\u00f1i FJ, Brimonidine\/Timolol Fixed Combination Study Group. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol. 2005;15:581\u201390.","journal-title":"Eur J Ophthalmol"},{"key":"796_CR17","doi-asserted-by":"publisher","first-page":"P41","DOI":"10.1016\/j.ophtha.2015.10.053","volume":"123","author":"Prum B, American academy of ophthalmology","year":"2016","unstructured":"Prum B, American Academy of Ophthalmology. Preferred Practice Patterns \u2212 Primary open-angle glaucoma. Ophthalmology. 2016;123:P41\u2013111.","journal-title":"Ophthalmology"},{"issue":"93\u20139","key":"796_CR18","first-page":"e4","volume":"151","author":"GL Spaeth","year":"2011","unstructured":"Spaeth GL, Bernstein P, Caprioli J, Schiffman RM. Control of intraocular pressure and fluctuation with fixed-combination brimonidine-timolol versus brimonidine or timolol monotherapy. Am J Ophthalmol. 2011;151:93-9.e4.","journal-title":"Am J Ophthalmol"},{"key":"796_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s10384-015-0420-2","volume":"60","author":"JM Kim","year":"2016","unstructured":"Kim JM, Kim TW, Kim CY, Kim HK, Park KH. Comparison of the intraocular pressure-lowering effect and safety of brimonidine\/timolol fixed combination and 0.5% timolol in normal-tension glaucoma patients. Jpn J Ophthalmol. 2016;60:20\u20136.","journal-title":"Jpn J Ophthalmol"},{"key":"796_CR20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10384-010-0855-4","volume":"54","author":"SW Cho","year":"2010","unstructured":"Cho SW, Kim JM, Park KH, Choi CY. Effects of brimonidine 0.2%-timolol 0.5% fixed-combination therapy for glaucoma. Jpn J Ophthalmol. 2010;54:407\u201313.","journal-title":"Jpn J Ophthalmol"},{"key":"796_CR21","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.1167\/iovs.06-0299","volume":"47","author":"AR Rudnicka","year":"2006","unstructured":"Rudnicka AR, Mt-Isa S, Owen CG, Cook DG, Ashby D. Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis. Invest Ophthalmol Vis Sci. 2006;47:4254\u201361.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"796_CR22","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/bjo.2005.081224","volume":"90","author":"HA Quigley","year":"2006","unstructured":"Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262\u20137.","journal-title":"Br J Ophthalmol"},{"key":"796_CR23","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.survophthal.2013.09.003","volume":"59","author":"HK Cho","year":"2014","unstructured":"Cho HK, Kee C. Population-based glaucoma prevalence studies in Asians. Surv Ophthalmol. 2014;59:434\u201347.","journal-title":"Surv Ophthalmol"},{"key":"796_CR24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3341\/kjo.2011.25.2.110","volume":"25","author":"JH Kim","year":"2011","unstructured":"Kim JH, Kang SY, Kim NR, Lee ES, Hong S, Seong GJ, et al. Prevalence and characteristics of glaucoma among Korean adults. Korean J Ophthalmol. 2011;25:110\u20135.","journal-title":"Korean J Ophthalmol"},{"key":"796_CR25","unstructured":"Allergan Korea Ltd. Combigan\u00ae (Brimonidine tartrate\/timolol maleate 0.2%\/0.68 % ophthalmic solution) Product Information. 2014. https:\/\/nedrug.mfds.go.kr\/pbp\/CCBBB01\/getItemDetail?itemSeq=200700952. Accessed 25 Mar 2020."},{"key":"796_CR26","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1053\/ejso.1998.0650","volume":"25","author":"A Mathew","year":"1999","unstructured":"Mathew A, Pandey M, Murthy NS. Survival analysis: caveats and pitfalls. Eur J Surg Oncol. 1999;25:321\u20139.","journal-title":"Eur J Surg Oncol"},{"key":"796_CR27","volume-title":"SAS\/STAT\u00ae 93 User\u2019s Guide: the LIFETEST procedure (Chapter)","author":"SAS Institute","year":"2011","unstructured":"SAS Institute. SAS\/STAT\u00ae 9.3 User\u2019s Guide: the LIFETEST procedure (Chapter). NC, USA: Cary; 2011."},{"key":"796_CR28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s10384-011-0110-7","volume":"56","author":"JW Cho","year":"2012","unstructured":"Cho JW, Sung KR, Yun SC, Na JH, Lee Y, Kook MS, et al. Progression detection in different stages of glaucoma: mean deviation versus visual field index - A visual field index for calculation of glaucoma rate of progression. Jpn J Ophthalmol. 2012;56:128\u201333.","journal-title":"Jpn J Ophthalmol"},{"key":"796_CR29","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ajo.2007.09.038","volume":"145","author":"B Bengtsson","year":"2008","unstructured":"Bengtsson B, Heijl A. A visual field index for calculation of glaucoma rate of progression. Am J Ophthalmol. 2008;145:343\u201353.","journal-title":"Am J Ophthalmol"},{"key":"796_CR30","unstructured":"Allergan plc. Highlights of prescribing information - Lumigan\u00ae 0.01% (bimatoprost ophthalmic solution). 2017. https:\/\/media.allergan.com\/actavis\/actavis\/media\/allergan-pdf-documents\/product-prescribing\/20170729-LUMIGAN-0-01%25-USPI-71807US15.pdf. Accessed 22 Dec 2020."},{"key":"796_CR31","unstructured":"Allergan plc Combigan\u00ae (brimonidine tartrate\/timolol maleate ophthalmic solution) 0.2%\/0.5% - highlights of prescribing information. 2015. https:\/\/media.allergan.com\/actavis\/actavis\/media\/allergan-pdf-documents\/product-prescribing\/20151015-Combigan-USPI-72060US15.pdf. (Accessed 6 Jan 2020)"},{"key":"796_CR32","first-page":"1","volume":"4","author":"EJ Higginbotham","year":"2010","unstructured":"Higginbotham EJ. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin Ophthalmol. 2010;4:1\u20139.","journal-title":"Clin Ophthalmol"},{"key":"796_CR33","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s10384-019-00673-8","volume":"63","author":"HJ Joh","year":"2019","unstructured":"Joh HJ, Jin SW. Comparison of different combinations of maximum medical therapy for lowering intraocular pressure in primary open angle glaucoma: 12-month retrospective consecutive case series. Jpn J Ophthalmol. 2019;63:322\u20137.","journal-title":"Jpn J Ophthalmol"},{"key":"796_CR34","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","volume":"120","author":"A Heijl","year":"2002","unstructured":"Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268\u201379.","journal-title":"Arch Ophthalmol"},{"key":"796_CR35","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0039-6257(00)00110-7","volume":"44","author":"MJ Doughty","year":"2000","unstructured":"Doughty MJ, Zaman ML. Human corneal thickness and its impact on intraocular pressure measures: a review and meta-analysis approach. Surv Ophthalmol. 2000;44:367\u2013408.","journal-title":"Surv Ophthalmol"},{"key":"796_CR36","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/j.ophtha.2007.04.068","volume":"114","author":"DK Dueker","year":"2007","unstructured":"Dueker DK, Singh K, Lin SC, Fechtner RD, Minckler DS, Samples JR, et al. Corneal thickness measurement in the management of primary open-angle glaucoma: a report by the American Academy of Ophthalmology. Ophthalmology. 2007;114:1779\u201387.","journal-title":"Ophthalmology"},{"key":"796_CR37","doi-asserted-by":"publisher","first-page":"202","DOI":"10.5935\/0004-2749.20170050","volume":"80","author":"R Gaspar","year":"2017","unstructured":"Gaspar R, Pinto LA, Sousa DC. Corneal properties and glaucoma: a review of the literature and meta-analysis. Arq Bras Oftalmol. 2017;80:202\u20136.","journal-title":"Arq Bras Oftalmol"},{"key":"796_CR38","doi-asserted-by":"publisher","first-page":"123","DOI":"10.18240\/ijo.2019.10.05","volume":"12","author":"ZZ Guo","year":"2019","unstructured":"Guo ZZ, Chang K, Wei X. Intraocular pressure fluctuation and the risk of glaucomatous damage deterioration: a meta-analysis. Int J Ophthalmol. 2019;12:123\u20138.","journal-title":"Int J Ophthalmol"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-020-00796-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10384-020-00796-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-020-00796-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T20:39:52Z","timestamp":1616099992000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10384-020-00796-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["796"],"URL":"https:\/\/doi.org\/10.1007\/s10384-020-00796-3","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,16]]},"assertion":[{"value":"7 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The conflicts of interest for S. W. Park, None; J. M. Kim, None; J. W. Lee, None; J. Maglambayan, Employee (AbbVie); S. Simonyi, Employee (AbbVie); K. H. Park, None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}